Press release
DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer
RAYNHAM, Mass. – (June 29, 2026) – DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced the appointment of Christina Zamarro as Chief Financial Officer, DePuy Synthes, effective July 13, 2026.
Zamarro brings over 25 years of financial leadership experience serving in multitude of roles across treasury, investor relations, FP&A and accounting. She joins DePuy Synthes from the Goodyear Tire & Rubber Company, a global manufacturer, where she most recently served as the Chief Financial Officer.
“I am excited to welcome Christina to the DePuy Synthes team,” said Namal Nawana, Worldwide President, DePuy Synthes. “With more than two decades of financial leadership, she brings deep experience managing global and complex transformation programs. I look forward to partnering closely with Christina as we continue building on our momentum.”
Throughout her career, Christina has advanced through leadership roles spanning treasury, investor relations, and FP&A. She held responsibility for capital markets, liquidity, and financial risk management globally before leading investor relations and later enterprise financial planning and performance management.
Christina earned an MBA from Vanderbilt University and a BA in Economics from Ohio Wesleyan University. She also serves on the board of L3Harris Technologies, where she is a member of the Audit Committee.
About DePuy Synthes
DePuy Synthes provides one of the most comprehensive orthopaedics portfolios in the world that helps heal and restore movement to the millions of patients we serve. Our solutions—including joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery, and sports medicine—alongside the VELYS™ Digital Surgery portfolio, are designed to support improved patient care and deliver clinical and economic value to healthcare systems worldwide. Building on a legacy of product innovation and industry firsts, we continue to shape the orthopaedic landscape through advancements in medical technologies and digital surgery across the continuum of care to Keep People Moving today and tomorrow.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in surgery, orthopaedics, vision, and cardiovascular solutions at https://www.jnjmedtech.com.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory actions; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
© Johnson & Johnson and its affiliates 2026. All rights reserved.
Media Contact:
Lindsey Diaz-MacInnis
Investor Contact:
Sandra Easton